EP1984004A4 - Glucane permettant d'améliorer une thérapie - Google Patents

Glucane permettant d'améliorer une thérapie

Info

Publication number
EP1984004A4
EP1984004A4 EP07718218A EP07718218A EP1984004A4 EP 1984004 A4 EP1984004 A4 EP 1984004A4 EP 07718218 A EP07718218 A EP 07718218A EP 07718218 A EP07718218 A EP 07718218A EP 1984004 A4 EP1984004 A4 EP 1984004A4
Authority
EP
European Patent Office
Prior art keywords
therapy
glucan
enhancing
enhancing glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07718218A
Other languages
German (de)
English (en)
Other versions
EP1984004A2 (fr
Inventor
Rolf Einar Engstad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcticzymes Technologies ASA
Memorial Sloan Kettering Cancer Center
Original Assignee
Biotec Pharmacon ASA
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/334,763 external-priority patent/US7906492B2/en
Application filed by Biotec Pharmacon ASA, Sloan Kettering Institute for Cancer Research filed Critical Biotec Pharmacon ASA
Publication of EP1984004A2 publication Critical patent/EP1984004A2/fr
Publication of EP1984004A4 publication Critical patent/EP1984004A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP07718218A 2006-01-17 2007-01-17 Glucane permettant d'améliorer une thérapie Withdrawn EP1984004A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/334,763 US7906492B2 (en) 2001-01-16 2006-01-17 Therapy-enhancing glucan
PCT/US2007/001427 WO2007084661A2 (fr) 2006-01-17 2007-01-17 Glucane permettant d'améliorer une thérapie

Publications (2)

Publication Number Publication Date
EP1984004A2 EP1984004A2 (fr) 2008-10-29
EP1984004A4 true EP1984004A4 (fr) 2010-03-03

Family

ID=40382391

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07718218A Withdrawn EP1984004A4 (fr) 2006-01-17 2007-01-17 Glucane permettant d'améliorer une thérapie

Country Status (4)

Country Link
EP (1) EP1984004A4 (fr)
JP (1) JP2009528267A (fr)
AU (1) AU2008207369B2 (fr)
WO (1) WO2007084661A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP5153188B2 (ja) * 2007-03-30 2013-02-27 小林製薬株式会社 Ｔｈ１／Ｔｈ２バランス改善剤
WO2009063221A2 (fr) * 2007-11-13 2009-05-22 Biotec Pharmacon Asa Procédés de traitement ou de prévention de maladies inflammatoires du tractus intestinal
JP5242855B2 (ja) * 2010-07-29 2013-07-24 国立大学法人北海道大学 免疫アジュバント
WO2012105219A1 (fr) * 2011-01-31 2012-08-09 オリンパス株式会社 Médicament stimulant l'effet thérapeutique d'anticorps
EP3373006A1 (fr) 2012-04-30 2018-09-12 Biothera, Inc. Procédés d'immunothérapie par bêta-glucane
EP2832360A1 (fr) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide pour utilisation dans la prévention de la formation de métastases et/ou de rechute
JP6893594B2 (ja) * 2014-07-10 2021-06-23 ハイバーセル，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
BR112020018761A2 (pt) * 2018-03-13 2020-12-29 Hibercell, Inc. Imunoterapia combinada com beta-glucano e agonista de cd40
WO2019209890A1 (fr) 2018-04-24 2019-10-31 Memorial Sloan Kettering Cancer Center Procédés d'amélioration de l'immunogénicité de vaccins spécifiques d'un antigène faiblement immunogènes à l'aide de bêta-glucanes de levure oraux
WO2020061203A1 (fr) * 2018-09-21 2020-03-26 Nantcell, Inc. Procédés et compositions pour moduler des cellules suppressives d'origine myéloïde
JP7048102B2 (ja) 2019-05-23 2022-04-05 国立研究開発法人医薬基盤・健康・栄養研究所 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817643A (en) * 1992-08-21 1998-10-06 Alpha-Beta Technology, Inc. Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
WO2002058711A1 (fr) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Glucane ameliorant une therapie
WO2005018544A2 (fr) * 2003-07-16 2005-03-03 Sloan-Kettering Institute For Cancer Research Glucane renforçateur de therapie
US20060009419A1 (en) * 2002-09-04 2006-01-12 Ross Gordon D Therapy-enhancing glucan
WO2006119395A2 (fr) * 2005-05-03 2006-11-09 Biopolymer Engineering, Inc. Compositions d'association d'agents therapeutiques, et leurs procedes d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340080C (fr) * 1985-03-11 1998-10-13 Dorothee Herlyn Methode de traitement des tumeurs chez l'humain
WO1991003495A1 (fr) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Procede de production de glucans solubles
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
EP0640348A1 (fr) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Mélange adjuvant à base d'huile et à base d'eau
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
WO1997035619A1 (fr) * 1996-03-28 1997-10-02 Genitrix, L.L.C. Cellules renforcees par opsonine, et procede de modulation d'une reponse immune a un antigene
JP2004507446A (ja) * 2000-02-04 2004-03-11 トーマス・ジェファーソン・ユニバーシティ 低用量ハプテン化腫瘍細胞および腫瘍細胞抽出物の免疫治療
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817643A (en) * 1992-08-21 1998-10-06 Alpha-Beta Technology, Inc. Underivatized, aqueous soluable β(1-3) glucan, composition and method of making same
WO2002058711A1 (fr) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Glucane ameliorant une therapie
US20060009419A1 (en) * 2002-09-04 2006-01-12 Ross Gordon D Therapy-enhancing glucan
WO2005018544A2 (fr) * 2003-07-16 2005-03-03 Sloan-Kettering Institute For Cancer Research Glucane renforçateur de therapie
WO2006119395A2 (fr) * 2005-05-03 2006-11-09 Biopolymer Engineering, Inc. Compositions d'association d'agents therapeutiques, et leurs procedes d'utilisation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL: "Medicinal importance of fungal beta-(1->3), (1->6)-glucans", MYCOLOGICAL RESEARCH, ELSEVIER, GB, vol. 111, no. 6, 1 June 2007 (2007-06-01), pages 635 - 652, XP022163026, ISSN: 0953-7562 *
CHEUNG N-K V ET AL: "Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 51, no. 10, 1 November 2002 (2002-11-01), pages 557 - 564, XP002297978, ISSN: 0340-7004 *
HERLYN D ET AL: "Stimulation of monoclonal antibody-dependent macrophage-mediated cytotoxicity against human tumors by lentinan", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 7, no. 3, 1 January 1985 (1985-01-01), pages 332, XP023842271, ISSN: 0192-0561, [retrieved on 19850101] *
HONG F ET AL: "Mechanism by which orally administered [beta]-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 2, 15 July 2004 (2004-07-15), pages 797 - 806, XP009125353, ISSN: 0022-1767 *
KANEKO Y ET AL: "Activity of lentinan against cancer and AIDS", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, BIOSCIENCE EDIPRINT INC., CAROUGE-GENEVA, CH, vol. 5, no. 4, 1 January 1989 (1989-01-01), pages 203 - 213, XP009125324, ISSN: 0255-9625 *
PELLEY R P ET AL: "Plants, polysaccharides and the treatment and prevention of neoplasia", CRITICAL REVIEWS IN ONCOGENESIS, BOCA RATON, FL, vol. 11, no. 3&4, 1 January 2000 (2000-01-01), pages 189 - 225, XP002963429, ISSN: 0893-9675 *
PENNA C ET AL: "PULMONARY METASTASES NEUTRALIZATION AND TUMOR REJECTION BY IN VIVO ADMINISTRATION OF BETA GLUCAN AND BISPECIFIC ANTIBODY", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 65, 1 January 1996 (1996-01-01), pages 377 - 382, XP002924638, ISSN: 0020-7136 *
VETVICKA V ET AL: "SOLUBLE BETA-GLUCAN POLYSACCHARIDE BINDING TO THE LECTIN SITE OF NEUTROPHIL OR NATURAL KILLER CELL COMPLEMENT RECEPTOR TYPE 3 (CD11B/CD18) GENERATES A PRIMED STATE OF THE RECEPTOR CAPABLE OF MEDIATING CYTOTOXICITY OF IC3B-OPSONIZED TARGET CELLS", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 98, no. 1, 1 July 1996 (1996-07-01), pages 50 - 61, XP001000371, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
JP2009528267A (ja) 2009-08-06
AU2008207369B2 (en) 2009-12-17
AU2008207369A1 (en) 2008-09-11
EP1984004A2 (fr) 2008-10-29
WO2007084661B1 (fr) 2008-01-10
WO2007084661A2 (fr) 2007-07-26
WO2007084661A3 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
IL195937A0 (en) Glucan preparation
DE602007002700D1 (en) Interventionsfreies frac-system
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007014031D1 (en) Luftreifensatz
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
EP1984004A4 (fr) Glucane permettant d'améliorer une thérapie
DE602007003855D1 (en) Isothermer reaktor
EP1983992A4 (fr) 2-imino-benzimidazoles
ZA200807821B (en) Thiazolyldihydroindazoles
DE602007001601D1 (en) Glasuntersuchung
DE602007006989D1 (en) Spiropiperidinderivate
ZA200807349B (en) Thiazolyl-dihydroquinazolines
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2007388A4 (fr) Opiopathies
GB2439623B (en) Tellmeuseby
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (fr) Sous-vetement
DE502007001126D1 (en) Eiten
GB0609741D0 (en) Cybertree
AU4914P (en) CalflatGL Calothamnus quadrifidus
AU3514P (en) ARCBENT Arctotis fastuosa
GB0609547D0 (en) My Gogglebox
GB0617481D0 (en) Modification
GB0609242D0 (en) Sudokube

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080814

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100202

17Q First examination report despatched

Effective date: 20100527

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121016